Similarly, the menin inhibitor revumenib, targeting KMT2A rearrangements and NPM1 mutations in acute leukemia, demonstrated deep and durable remissions in phase I/II studies [208], culminating in FDA approval in 2024 as the first agent in its class. Here, KMT2A is linked to acute leukemia.